Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BBIO vs BHVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHVN Captures Overall Composite Edge (42.1 HOLD vs 44.5 HOLD), While BBIO Leads 3–2 on Growth & Valuation Pillars

BHVN Overall Winner 6-Pillar Tally: BBIO 3 – 2 BHVN (1 Tie) Matrix Metrics: BBIO 4 – 4 BHVN

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over BridgeBio Pharma, Inc. (BBIO) on higher Unified Composite conviction (42.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while BBIO wins 3–2 across the 6-pillar growth and valuation breakdown. BBIO trades at $77.18 (N/M Forward P/E, -37.3% operating margin) versus BHVN at $13.90 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While BBIO currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -37.3% operating margin) and revenue trajectory (+0.0% vs. +192.6% YoY).
  • Technical & Structure Timing Caution: BBIO trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.8); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BBIO vs BHVN
BBIO NASDAQ
BridgeBio Pharma, Inc. Common Stock
Pharmaceutical Preparations
$77.18
-1.43% 1D
Market Cap $15.2B
TTM Revenue $946M
Forward P/E N/M
Beta / 30D Vol 0.88β · 38% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 19.0 Fund 40.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 61
RSI-14: 60.8 · SMA20: $73.56 · SMA50: $70.03
BHVN NYSE Head-to-Head Winner
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48

6-Pillar Scorecard Institutional Category Breakdown (BBIO 3 – 2 BHVN)

Columns: Metric · BBIO · BHVN
1. Valuation Multiples BBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 17.1x N/M
2. Growth & Scale BBIO
Revenue Growth (YoY) +192.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $946M N/A
Market Cap $15.2B $2.1B
3. Profitability & Quality BHVN
Gross Margin 94.3% N/A
Operating Margin -37.3% 0.0%
Net Profit Margin -59.8% 0.0%
Return on Equity (ROE) -1789.7% -799.5%
4. Balance Sheet & Cash Flow BBIO
Cash Generation (TTM) -$370M -$473M
Cash Flow Margin -39.1% N/A
Net Cash / Leverage $961M Net Debt $205M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHVN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 44.0% (3rd %ile) 91.5% (18th %ile)
Put/Call OI Skew 1.68x (Put-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BBIO (4) vs BHVN (4)
Institutional Metric BBIO BHVN Criterion Row Edge
Market Capitalization
Scale
$15.2B $2.1B Larger Scale BBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+192.6% +0.0% Higher Growth BBIO
Operating Margin (TTM)
Profitability
-37.3% 0.0% Higher Margin BHVN
Net Profit Margin
Profitability
-59.8% 0.0% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-1789.7% -799.5% Higher ROE BHVN
52-Week Range Position
Momentum
48% ($62–$93) 59% ($8–$18) Stronger Trend BHVN
Beta / 30D Volatility
Risk Regime
0.88β · 38% Vol 1.41β · 111% Vol Lower Realized Risk BBIO
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite BBIO
Trailing 12M Revenue (USD)
Operating Scale
$946M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$370M ($961M Net Debt) -$473M ($205M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +12.74 pp
BBIO: +16.25% · BHVN: +28.99%
3M Horizon BHVN +9.46 pp
BBIO: -6.99% · BHVN: +2.47%
6M Horizon BHVN +45.62 pp
BBIO: +18.16% · BHVN: +63.78%
1Y Horizon BHVN +53.46 pp
BBIO: +18.63% · BHVN: +72.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BBIO vs BHVN. Trailing 12-month operating profitability (BBIO -37.3% vs BHVN 0.0%) and valuation multiples (BBIO N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$946M
Gross Margin94.3%
Op. Margin-37.3%
ROE / Fwd P/E-1789.7% · N/M
BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BBIO CONSOLIDATION
91d in phase · OBV ACCUMULATION
Current IV 44.0%
IV Percentile 3rd %ile
Put/Call OI Skew 1.68x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2B market capitalization and -37.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BBIO vs BHVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over BridgeBio Pharma, Inc. (BBIO) on higher Unified Composite conviction (42.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while BBIO wins 3–2 across the 6-pillar growth and valuation breakdown. BBIO trades at $77.18 (N/M Forward P/E, -37.3% operating margin) versus BHVN at $13.90 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BBIO currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -37.3% operating margin) and revenue trajectory (+0.0% vs. +192.6% YoY). Technical & Structure Timing Caution: BBIO trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.8); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BBIO leads the Growth & Scale pillar: BBIO posts +192.6% YoY revenue growth and +0.0% YoY earnings growth on $946M TTM revenue (94.3% gross margin, -37.3% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BBIO generates $946M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, BBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.

BBIO screens cheaper on headline valuation multiples. BBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.1x EV/Revenue (-39.1% FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BBIO (-1789.7% ROE) versus BHVN (-799.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BBIO carries 44.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 1.68x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.88β · 38% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.